Evaluation of feasibility phase of adaptive version of locally made bubble continuous positive airway pressure oxygen therapy for the treatment of COVID-19 positive and negative adults with severe pneumonia and hypoxaemia

• Published in: Journal of global health Vol. 13; p. 06046
• Main Authors: Chisti, Mohammod Jobayer, Rahman, Ahmed Ehsanur, Hasan, Taufiq, Ahmed, Tahmeed, El Arifeen, Shams, Clemens, John David, Rahman, Abu Sayem Mirza Md. Hasibur, Uddin, Md. Fakhar, Amin, Md. Robed, Miah, Md. Titu, Islam, Md. Khairul, Sharif, Mohiuddin, Shahid, Abu Sadat Mohammad Sayeem Bin, Ahmed, Anisuddin, Banik, Goutom, Rashid, Meemnur, Ahmed, Md. Kawsar, Shahrin, Lubaba, Afroze, Farzana, Sarmin, Monira, Nuzhat, Sharika, Sarkar, Supriya, Islam, Jahurul, Islam, Muhammad Shariful, Norrie, John, Campbell, Harry, Nair, Harish, Cunningham, Steve
• Format: Journal Article
• Language: English
• Published: Edinburgh Edinburgh University Global Health Society 01-01-2023
• Subjects: Adults; Continuous positive airway pressure; COVID-19; Fatalities; Feasibility studies; Global health; Hospitals; Informed consent; Intensive care; Medical personnel; Medical research; Nurses; Oxygen; Oxygen therapy; Pandemics; Physicians; Pneumonia; Severe acute respiratory syndrome coronavirus 2; Ventilators; X-rays; Bangladesh
• ISSN: 2047-2978; 2047-2986
• DOI: 10.7189/jogh.13.06046

BackgroundBubble continuous positive airway pressure (bCPAP) oxygen therapy has been shown to be safe and effective in treating children with severe pneumonia and hypoxaemia in Bangladesh. Due to lack of adequate non-invasive ventilatory support during coronavirus disease 2019 (COVID-19) crisis, we aimed to evaluate whether bCPAP was safe and feasible when adapted for use in adults with similar indications.MethodsAdults (18-64 years) with severe pneumonia and moderate hypoxaemia (80 to <90% oxygen saturation (SpO2) in room air) were provided bCPAP via nasal cannula at a flow rate of 10 litres per minute (l/min) oxygen at 10 centimetres (cm) H2O pressure, in two tertiary hospitals in Dhaka, Bangladesh. Qualitative interviews and focus group discussions, using a descriptive phenomenological approach, were performed with patients and staff (n = 39) prior to and after the introduction (n = 12 and n = 27 respectively) to understand the operational challenges to the introduction of bCPAP.ResultsWe enrolled 30 adults (median age 52, interquartile range (IQR) 40-60 years) with severe pneumonia and hypoxaemia and/or acute respiratory distress syndrome (ARDS) irrespective of coronavirus disease 2019 (COVID-19) test results to receive bCPAP. At baseline mean SpO2 on room air was 87% (±2) which increased to 98% (±2), after initiation of bCPAP. The mean duration of bCPAP oxygen therapy was 14.4 ± 24.8 hours. There were no adverse events of note, and no treatment failure or deaths. Operational challenges to the clinical introduction of bCPAP were lack of functioning pulse oximeters, difficult nasal interface fixation among those wearing nose pin, occasional auto bubbling or lack of bubbling in water-filled plastic bottle, lack of holder for water-filled plastic bottle, rapid turnover of trained clinicians at the hospitals, and limited routine care of patients by hospital clinicians particularly after official hours.DiscussionIf the tertiary hospitals in Bangladesh are supplied with well-functioning good quality pulse oximeters and enhanced training of the doctors and nurses on proper use of adapted version of bCPAP, in treating adults with severe pneumonia and hypoxaemia with or without ARDS, the bCPAP was found to be safe, well tolerated and not associated with treatment failure across all study participants. These observations increase the confidence level of the investigators to consider a future efficacy trial of adaptive bCPAP oxygen therapy compared to WHO standard low flow oxygen therapy in such patients.Conclusions Although bCPAP oxygen therapy was found to be safe and feasible in this pilot study, several challenges were identified that need to be taken into account when planning a definitive clinical trial.